Last reviewed · How we verify
AGN-CognI.Q
At a glance
| Generic name | AGN-CognI.Q |
|---|---|
| Also known as | INM®176 |
| Sponsor | Milton S. Hershey Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Angelica Gigas Dietary Supplements and Human Immune Cells (NA)
- AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AGN-CognI.Q CI brief — competitive landscape report
- AGN-CognI.Q updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI